Literature DB >> 8839686

Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

A Llerena1, J Cobaleda, C Martínez, J Benítez.   

Abstract

Genetic and environmental factors are determinants of the interindividual and interethnic variability in drug metabolism. The metabolism of several important drugs (e.g. haloperidol) cosegregates with that of debrisoquine. Thus, interethnic differences in debrisoquine hydroxylation polymorphism (CYP2D6) might be partly responsible for the variation in haloperidol disposition between races. The influence of tobacco, ethanol, caffeine, gender, and oral contraceptive use on the debrisoquine metabolic ratio (MR) has been analyzed in 633 Spanish healthy volunteers. MR was also determined in panels of healthy volunteers. 18 smokers were studied during a tobacco abstinence period, and 31 women three times during the same menstrual cycle. Among EMs, debrisoquine MR was significantly (P < 0.05) lower during smoking cessation (mean antilog +/- SD, 0.48 +/- 0.29) compared to a smoking period (0.61 +/- 0.23). During the lutheal phase of the menstrual cycle, debrisoquine MR was also significantly (P < 0.01) lower (0.33 +/- 0.41) compared to the ovulatory-phase (0.41 +/- 0.34) and the phase before ovulation (0.44 +/- 0.36). Among EMs, it is suggested that debrisoquine MR may be modified by tobacco smoking and sexual hormones. The clinical relevance of these findings remains unclear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839686     DOI: 10.1007/BF03190261

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  45 in total

1.  The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.

Authors:  H B Niznik; R F Tyndale; F R Sallee; F J Gonzalez; J P Hardwick; T Inaba; W Kalow
Journal:  Arch Biochem Biophys       Date:  1990-02-01       Impact factor: 4.013

2.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

Authors:  K W Bock; D Schrenk; A Forster; E U Griese; K Mörike; D Brockmeier; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1994-08

3.  Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Authors:  M Eichelbaum; M P Baur; H J Dengler; B O Osikowska-Evers; G Tieves; C Zekorn; C Rittner
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

4.  Poor metabolisers of nicotine and CYP2D6 polymorphism.

Authors:  S Cholerton; A Arpanahi; N McCracken; C Boustead; H Taber; E Johnstone; J Leathart; A K Daly; J R Idle
Journal:  Lancet       Date:  1994-01-01       Impact factor: 79.321

5.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.

Authors:  M S Lennard; P R Jackson; S Freestone; G T Tucker; L E Ramsay; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

6.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Pregnancy-induced increase in metoprolol metabolism.

Authors:  S Högstedt; B Lindberg; D R Peng; C G Regårdh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

10.  Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.

Authors:  A Llerena; G Edman; J Cobaleda; J Benítez; D Schalling; L Bertilsson
Journal:  Acta Psychiatr Scand       Date:  1993-01       Impact factor: 6.392

View more
  8 in total

1.  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Authors:  S Hägg; O Spigset; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.

Authors:  Adrián LLerena; Roland Berecz; Alfredo de la Rubia; Pedro Dorado
Journal:  Eur J Clin Pharmacol       Date:  2002-06       Impact factor: 2.953

Review 3.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.

Authors:  Roland Berecz; Alfredo de la Rubia; Pedro Dorado; Pedro Fernández-Salguero; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-03-28       Impact factor: 2.953

Review 5.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Stereoselective steady state disposition and action of propafenone in Chinese subjects.

Authors:  G Li; P L Gong; J Qiu; F D Zeng; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

7.  Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

Authors:  Adrián LLerena; Pedro Dorado; Roland Berecz; Antonio P González; Eva M Peñas-LLedó
Journal:  Eur J Clin Pharmacol       Date:  2004-01-16       Impact factor: 2.953

8.  Sex-dependent modulation of treatment response.

Authors:  David R Rubinow; Molly Moore
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.